High-dose Influenza Vaccine Study for People Ages 50-64

01 Nov High-dose Influenza Vaccine Study for People Ages 50-64

We are currently recruiting people ages 50 to 64 who have not yet received this season’s (2024-2025) influenza (flu) vaccine to participate in a clinical trial of an investigational flu vaccine. This Phase 3 trial, sponsored by Sanofi, will evaluate how well an investigational high-dose flu vaccine protects against flu infection compared with a licensed standard-dose flu vaccine. The study will only be open to enrollment for a few weeks.

• Participants will receive one injection of either the investigational high-dose flu vaccine or a licensed standard-dose flu vaccine. Participants will not know which of the two vaccines they receive. The high-dose flu vaccine in this study is approved in the US for use in people aged 65 and older.
• The study involves two in-person study visits at our research clinic in downtown Seattle during the first month of the study.
• Participants will be asked to answer questions in a phone app for 8 days to let us know whether they have any reactions after the vaccine.
• Participants will receive a $50 gift card after each in-person visit completed.
• There will be a telephone contact about 6 months after enrollment, and participants will receive a $25 gift card after that call is completed.
• We will provide free parking in our research clinic building’s garage or bus tickets at each visit.

Participant Eligibility

• Healthy adults aged 50 to 64 years
• Able to attend study visits at the Kaiser Permanente Washington Health Research Institute clinic in downtown Seattle
• No medical conditions that affect the immune system and not taking medications that affect the immune system
• No receipt of flu vaccine in the 6 months before enrollment
• There are other conditions that may make you ineligible for this study

Contact

Maya Dunstan
(206) 287-2061